EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC 4.0

Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1

Masakazu Toi iD, Frances Boyle, Young-Hyuck Im, Mattea Reinisch, David Molthrop, Zefei Jiang, Ran Wei, Francisco Sapunar, Brenda R Grimes, Sarah Cassidy Nabinger, Stephen R D Johnston

The Oncologist · 18.01.2023 · 28 (1) · e77-e81

DOI: 10.1093/oncolo/oyac234 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift The Oncologist, online erschienen am 07.11.2022. Verfasst von Masakazu Toi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Kyoto University Hospital, Kyoto, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The monarchE Cohort 1 patient population was enrolled based on high-risk clinicopathological features that can easily be identified as part of routine clinical breast cancer evaluation. Efficacy data from Cohort 1 demonstrate substantial evidence of benefit for adjuvant abemaciclib+ET in patients with HR+, HER2− early breast cancer at high risk of recurrence (ClinicalTrials.gov: NCT03155997 [monarchE]).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansAminopyridinesAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesProtein Kinase Inhibitors

Stichwörter der Autor:innen

CDK4/6Ki-67abemaciclibadjuvantearly breast cancer

Substanzen

AminopyridinesBenzimidazolesProtein Kinase InhibitorsErb-b2 Receptor Tyrosine Kinasesabemaciclib

Autor:innen und Institutionen

  • Department of Breast Surgery, Kyoto University Hospital, Kyoto, Japan.
  • Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital, Sydney, Australia.
  • University of Sydney, Sydney, Australia.
  • Division of Hematology/Medical Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Breast Unit, Kliniken Essen-Mitte, Essen, Germany.
  • Hematology and Oncology, Florida Cancer Specialists & Research Institute, Orlando, FL, USA.

ORCID-Profile: Masakazu Toi

Förderung

  • Eli Lilly and Company

Zitieren

APA

Toi, M., Boyle, F., Im, Y. H., Reinisch, M., Molthrop, D., Jiang, Z., Wei, R., Sapunar, F., Grimes, B. R., Nabinger, S. C., & Johnston, S. R. D. (2023). Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1. The Oncologist, 28(1), e77-e81. https://doi.org/10.1093/oncolo/oyac234

Vancouver

Toi M, Boyle F, Im YH, Reinisch M, Molthrop D, Jiang Z, et al. Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1. The Oncologist. 2023;28(1):e77-e81. doi:10.1093/oncolo/oyac234

BibTeX
@article{Toi2023,
  author = {Toi, Masakazu and Boyle, Frances and Im, Young-Hyuck and Reinisch, Mattea and Molthrop, David and Jiang, Zefei and Wei, Ran and Sapunar, Francisco and Grimes, Brenda R and Nabinger, Sarah Cassidy and Johnston, Stephen R D},
  title = {Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1},
  journal = {The Oncologist},
  year = {2023},
  volume = {28},
  number = {1},
  pages = {e77--e81},
  doi = {10.1093/oncolo/oyac234}
}
Kostenlos starten →